Phase 2 / Phase 3Active, not recruitingINTERVENTIONAL
Management of Castration-Resistant Prostate Cancer with Oligometastases
ClinicalTrials.gov · NCT02685397 · Registry updated: 2024-12-04
- Condition / research focus
- Castration-resistant Prostate Cancer Patients with Oligometastases
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Countries with listed sites
- Canada
- Registry dates and results
- Start: 2016-10. Completion: 2041-08 (may be estimated). No results posted in this registry response.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Leuprolide Acetate (drug) — also listed as: Eligard, Lupron
- Goserelin Acetate (drug) — also listed as: ZOLADEX
- Triptorelin (drug) — also listed as: Trelstar
- Enzalutamide (drug) — also listed as: Xtandi
- Stereotactic Body Radiation Therapy (radiation) — also listed as: SBRT
Where the study takes place — 11 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.